Overview

Study of Trilipix Effects on Lipids and Arteries

Status:
Terminated
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
Fibrates reduce atherosclerosis and cardiovascular disease events. A major mechanism of this benefit appears to be their ability to raise plasma high density lipoprotein cholesterol (HDL-C), especially in patients with high triglyceride levels. This study will investigate the effects of the addition of Trilipix (fenofibric acid) versus placebo to ongoing statin treatment on high density lipoprotein (HDL) composition and arterial function in subjects with insulin resistance.
Phase:
Phase 4
Details
Lead Sponsor:
University of Utah
Collaborator:
Abbott
Treatments:
Fenofibrate
Fenofibric acid